2025-05-29 - Analysis Report
Okay, here's a report based on the data you provided, designed to be informative and concise.

**Report: RXRX (Recursion Pharmaceuticals Inc) Analysis**

**0. Preliminary Numbers:**

*   **Ticker:** RXRX
*   **Company:** Recursion Pharmaceuticals Inc.
*   **Current Price:** $4.395

**1. Performance vs. S&P 500 (VOO):**

*   **RXRX Cumulative Return:** -61.32%
*   **VOO Cumulative Return:** 14.95%
*   **Divergence (RXRX - VOO):** -76.27%
*   **Relative Divergence:** 0.8 (Near the bottom of its historical range).

*   **Company Overview:** Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science and engineering.

**Alpha/Beta Analysis Table:**

| Year        | CAGR    | MDD     | Alpha   | Beta   | Cap(B) |
|-------------|---------|---------|---------|--------|--------|
| 2021-2023   | 5.0%    | 73.6%   | 1.0%    | -0.1   | 4.0    |
| 2022-2024   | 0.0%    | 73.6%   | -17.0%  | -0.1   | 2.7    |
| 2023-2025   | -10.0%   | 73.6%   | -40.0%  | -0.1   | 1.8    |

*   **Analysis of Provided Table:**
    *   **Cumulative Returns:** RXRX has significantly underperformed the S&P 500. The negative divergence indicates substantial underperformance relative to the benchmark. The relative divergence of 0.8 suggests RXRX is currently near its lowest point compared to its historical performance relative to the S&P 500.
    *   **Alpha/Beta Analysis Table:** The table highlights a concerning trend of declining performance. The negative Alpha values, especially in recent periods, show RXRX is generating significantly lower returns than expected based on market movements (S&P 500). The negative Beta suggests a slight inverse correlation with the market, though the value is close to zero. The declining CAGR and decreasing market capitalization further emphasize the challenges RXRX is facing. The high Maximum Drawdown (MDD) indicates substantial risk and volatility.

**2. Recent Price Action:**

*   **Current Price:** $4.395
*   **Previous Close:** $4.39
*   **Change:** +$0.11 (+0.11%)
*   **5-Day Moving Average:** $4.221
*   **20-Day Moving Average:** $4.5523
*   **60-Day Moving Average:** $5.3543

**3. Technical Indicators:**

*   **Market Risk Indicator (MRI):** 0.366 (Low Risk)
*   **RSI:** 54.57 (Neutral)
*   **PPO:** 0.30 (Neutral)
*   **Hybrid Signal:** cash_14%_Buy 80% of cash (2445 shares - Caution - MRI:0.37)
*   **Delta_Previous_Relative_Divergence:** -1.0 (Short-term decline)
*   **Expected Return (%):** -2391.7 (Significantly negative long-term outlook relative to the S&P 500).
*   **Price Change Reflection:** The slight increase in price from the previous close, as shown by {'price': 4.395, 'previousClose': 4.39, 'change': 0.11}, indicates a minor positive movement in the stock price.

**4. Recent News & Significant Events:**

*   **2025-05-26:** RXRX has made headlines due to major business developments, regulatory changes, or market events.
*   **2025-05-28:** Analysts are discussing RXRX's recent performance and outlook.
*   **2025-05-27:** RXRX's stock has shown notable volatility.
*   **2025-05-25:** Market experts highlight both risks and opportunities.

**5. Overall Analysis:**

RXRX (Recursion Pharmaceuticals Inc) has significantly underperformed the S&P 500, with a substantial negative divergence. Its recent price action shows a very slight positive movement, but it remains below its 20-day and 60-day moving averages, suggesting continued downward pressure. The negative Alpha values and declining market capitalization highlight significant underperformance relative to the market, while the high Maximum Drawdown (MDD) underscores the stock's high risk and volatility.

Technical indicators present a mixed picture. The MRI suggests a low-risk market environment, but the Hybrid Signal advises caution. The negative change in relative divergence indicates a short-term decline, and the expected return is extremely negative, indicating a poor long-term outlook compared to the S&P 500.

Recent news suggests potential major developments and analyst scrutiny, contributing to stock volatility. Market experts highlight both risks and opportunities, advising investors to monitor news and announcements closely.

**In conclusion, RXRX faces significant challenges. The company's negative performance relative to the S&P 500, coupled with concerning financial metrics and volatility, suggests a cautious approach is warranted. Investors should carefully consider the risks and opportunities while closely monitoring recent news and company announcements.**
